Apollomics Inc.
Apollomics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing oncology therapies for cancer treatment. The company’s current pipeline centers on targeted medicines and immuno-oncology approaches designed to address molecular drivers of disease and support use alongside other treatment options. Its lead programs include vebreltinib, an oral c-Met inhibitor being studied in solid tumors with MET dysregulation, and APL-102, an oral multi-kinase inhibitor in early-stage cancer development. Apollomics also evaluates therapies for difficult-to-treat cancers such as non-small cell lung cancer and acute myeloid leukemia. Based in Foster City, California, Apollomics operates as a specialized biotechnology company within the broader oncology drug-development market, where it contributes experimental therapies aimed at precision medicine and unmet medical needs.
$21.10
+$0.10 (+0.48%)
EOD Oct 16, 2026
The business is unprofitable at the operating level (-108.16% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
ROIC dropped from -128.39% to -224.42%, capital efficiency is deteriorating. Negative free cash flow of -$10M. The business is consuming cash, not generating it.
Price History
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$9M
Net Income (TTM)
-$11M
▲ +79.7% YoY
Op. Margin
-108.16%
ROIC
-224.42%
▼ -96.0pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$10M
▲ +64.0% YoY
Op. Cash Flow (TTM)
-$10M
▲ +63.9% YoY
Net Debt
-$3M
Net Cash Position
Cash & Equiv.
$3M
Continue Research
Is Apollomics (APLM) overvalued?
Apollomics (APLM)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Apollomics scores 20/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from company filings; read the full methodology, or see how the market compares in our US profitability statistics. This is analysis, not investment advice.
Frequently asked
Is Apollomics a high-quality business?+
Apollomics scores 20 out of 100 on Intrinsiqq's quality score, a weighted blend of 4 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -108.2% operating margin and a -224.4% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from company filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
Is Apollomics a good stock to buy right now?+
That depends on valuation and quality together, not either alone. you should weigh APLM's valuation and scores 20/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from company filings, not investment advice.
Related stocks: Biotechnology
Spot a number that looks wrong?
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.